Wyeth's Prevenar to be in UK immunization program
US drug major Wyeth's pneumococcal conjugate vaccine Prevenar is to be included the UK's childhood immunization program with effect from September 4, a decision which has been welcomed by the company's local subsidiary.
Wyeth UK medical director David Gillen said: "it is estimated that 50 babies and children under five die from serious pneumococcal diseases, such as meningitis and septicemia, each year, with many more left with life-long disabilities, such as cerebral palsy, deafness and blindness."
The firm added that it has already begun supplying the vaccine to the Department of Health in preparation for the start of the immunization program.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze